Patents Assigned to Cymabay Therapeutics, Inc.
  • Treatment of NAFLD and NASH
    Patent number: 10722483
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: July 28, 2020
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Treatment of obesity and its complications
    Publication number: 20200155487
    Abstract: Combination treatment of obesity and its complications with seladelpar or a salt thereof and a glucagon-like peptide-1 (GLP-1) receptor agonist.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 21, 2020
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Yun-Jung Choi, Charles A McWherter
  • Combination treatment of NAFLD and NASH
    Publication number: 20200155650
    Abstract: Combination treatment of NAFLD, including NASH, with seladelpar or a salt thereof and a glucagon-like peptide-1 (GLP-1) receptor agonist.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 21, 2020
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Yun-Jung Choi, Charles A. McWherter
  • Treatment of intrahepatic cholestatic diseases
    Publication number: 20200061006
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 27, 2020
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of NAFLD and NASH
    Publication number: 20200009092
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: May 23, 2019
    Publication date: January 9, 2020
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 10512622
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 24, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 10478411
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: November 19, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
    Publication number: 20190298672
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 3, 2019
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • Treatment of intrahepatic cholestatic diseases
    Publication number: 20190255004
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: August 22, 2019
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of NAFLD and NASH
    Patent number: 10342770
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 9, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Treatment of intrahepatic cholestatic diseases
    Publication number: 20190192459
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 27, 2019
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
    Patent number: 10292983
    Abstract: Use of oxymethylene aryl GPR119 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 21, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventor: Charles A. McWherter
  • Treatment of NAFLD and NASH
    Publication number: 20190142776
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: December 17, 2018
    Publication date: May 16, 2019
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 10272058
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: April 30, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 10220011
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 5, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment for NAFLD and NASH
    Patent number: 10188620
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 29, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 10137112
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 27, 2018
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
    Patent number: 10098843
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 16, 2018
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Treatment of NAFLD and NASH
    Publication number: 20180228752
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 16, 2018
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Publication number: 20180214420
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 2, 2018
    Applicants: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter